Over-expression of BCAT1 is a prognostic marker in gastric cancer

Publication date: Available online 13 February 2018
Source:Human Pathology
Author(s): Yuan Xu, Weiming Yu, Taotao Yang, Miaozun Zhang, Chao Liang, Xianlei Cai, Qinshu Shao
As one form of branched chain amino-acid transaminase(BCAT) enzymes, It has been found that up-regulation of BCAT1 is associated with poor prognosis in numerous types of tumors, but studies on the role of BCAT1 expression in gastric cancer(GC) are rare. The aim of this study was to detect BCAT1 expression in (GC) and to analyze its association with prognosis of GC patients.Microarray experiments were performed on the Affymetrix U133 plus 2.0 GeneChip Array. The protein and mRNA levels of BCAT1 were validated by immunohistochemistry (IHC) and Real-Time quantitative PCR (RT-qPCR) in GC tissues and adjacent noncancerous tissues (ANCT). Our study shows that the expression of BCAT1 significantly increased in human gastric cancer. Furthermore, it can also be found that BCAT1 over-expression was associated with TMN stage (P < .05), local invasion (P < .05), Lauren type (P < .05), tumor classification(P < .05), lymph node metastasis (P < .05) and presence of distant metastasis (P < .05).Kaplan–Meier survival analysis revealed that high BCAT1 expression predicted significantly worse over survival(OS) (P < .05) while Multivariate Cox regression analysis showed that BCAT1 affects gastric cancer independently. In conclusion, up-regulation of BCAT1 indicated a poor survival rate of gastric cancer and may serve as a useful marker for predicting the outcome of patients with GC.



http://ift.tt/2GcquaT